ALNYLAM PHARMACEUTICALS, INC. (ALNY) Operating Margin
- Operating margin · 12 months: Value 20.81%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 20.81% | Operating income / revenue. Period ending 2026-06-30. $999.78M ÷ $4.80B × 100 ≈ 20.81% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 999.78M USD | Operating Income (Loss) |
| Revenue | 4.80B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 970.74M USD | Cost of Goods and Services Sold |
| Research and development | 1.51B USD | Research and Development Expense |
| Selling, general and administration | 1.32B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $999.78M | $4.80B | $970.74M | $1.51B | $1.32B | 20.81% |
| 2025-12-31 | $501.58M | $3.71B | $677.17M | $1.32B | $1.21B | 13.51% |
| 2025-09-30 | $264.70M | $3.21B | $512.09M | $1.25B | $1.18B | 8.25% |
| 2025-06-30 | $-180.19M | $2.46B | $396.84M | $1.16B | $1.08B | -7.32% |
| 2025-03-31 | $-115.37M | $2.35B | $322.08M | $1.13B | $1.00B | -4.91% |
| 2024-12-31 | $-176.88M | $2.25B | $306.51M | $1.13B | $975.53M | -7.87% |
| 2024-09-30 | $-188.13M | $2.09B | $275.84M | $1.10B | $878.31M | -8.98% |
| 2024-06-30 | $102.64M | $2.34B | $273.33M | $1.08B | $856.49M | 4.38% |
| 2024-03-31 | $-175.80M | $2.00B | $281.40M | $1.03B | $822.78M | -8.78% |
| 2023-12-31 | $-282.18M | $1.83B | $268.22M | $1.00B | $795.65M | -15.43% |
| 2023-09-30 | $-354.38M | $1.72B | $242.41M | $994.31M | $807.87M | -20.56% |
| 2023-06-30 | $-826.29M | $1.24B | $199.45M | $986.50M | $844.55M | -66.78% |
| 2023-03-31 | $-788.15M | $1.14B | $158.15M | $943.69M | $799.85M | -68.93% |
| 2022-12-31 | $-785.07M | $1.04B | $140.17M | $883.01M | $770.66M | -75.68% |
| 2022-09-30 | $-791.02M | $960.92M | $127.64M | $850.03M | $746.70M | -82.32% |
| 2022-06-30 | $-714.66M | $884.25M | $119.22M | $799.23M | $652.91M | -80.82% |
| 2022-03-31 | $-669.13M | $879.98M | $115.44M | $776.15M | $628.25M | -76.04% |
| 2021-12-31 | $-708.65M | $844.29M | $115.00M | $792.16M | $620.64M | -83.93% |
| 2021-09-30 | $-708.31M | $749.31M | $107.03M | $731.58M | $600.55M | -94.53% |
| 2021-06-30 | $-751.84M | $687.53M | $99.76M | $698.79M | $625.95M | -109.35% |
| 2021-03-31 | $-804.53M | $570.94M | $87.77M | $671.15M | $608.52M | -140.91% |
| 2020-12-31 | $-828.44M | $492.85M | $78.05M | $654.82M | $588.42M | -168.09% |
| 2020-09-30 | $-932.29M | $400.97M | $67.20M | $687.65M | $578.41M | -232.51% |
| 2020-06-30 | $-923.39M | $345.18M | $50.62M | $686.66M | $531.28M | -267.51% |
| 2020-03-31 | $-960.80M | $285.93M | $35.02M | $695.56M | $516.16M | -336.02% |
| 2019-12-31 | $-939.43M | $219.75M | $25.06M | $655.11M | $479.00M | -427.50% |
| 2019-09-30 | $-861.71M | $169.10M | $14.55M | $584.85M | $431.42M | -509.58% |
| 2019-06-30 | $-899.97M | $101.11M | $9.47M | $564.00M | $427.61M | -890.09% |
| 2019-03-31 | $-856.06M | $86.30M | (m) | $537.69M | $399.52M | -991.92% |
| 2018-12-31 | $-814.67M | $74.91M | $1.80M | $505.42M | $382.36M | -1087.56% |
| 2018-09-30 | $-741.62M | (m) | (m) | $492.16M | (m) | (m) |
| 2018-06-30 | $-612.86M | (m) | (m) | $447.46M | (m) | (m) |
| 2018-03-31 | $-540.98M | (m) | (m) | $400.51M | (m) | (m) |
| 2018-01-01 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-500.09M | (m) | (m) | $390.63M | (m) | (m) |
| 2017-09-30 | $-468.22M | (m) | (m) | $377.87M | (m) | (m) |
| 2017-06-30 | $-449.09M | (m) | (m) | $380.56M | (m) | (m) |
| 2017-03-31 | $-421.07M | (m) | (m) | $373.10M | (m) | (m) |
| 2016-12-31 | $-424.59M | (m) | (m) | $382.39M | (m) | (m) |
| 2016-09-30 | $-401.67M | (m) | (m) | $360.22M | (m) | (m) |
| 2016-06-30 | $-373.32M | (m) | (m) | $330.90M | (m) | (m) |
| 2016-03-31 | $-353.81M | (m) | (m) | $314.73M | (m) | (m) |
| 2015-12-31 | $-296.01M | (m) | (m) | $276.50M | (m) | (m) |
| 2015-09-30 | $-249.21M | (m) | (m) | $249.21M | (m) | (m) |
| 2015-06-30 | $-216.08M | (m) | (m) | $226.86M | (m) | (m) |
| 2015-03-31 | $-188.14M | (m) | (m) | $204.53M | (m) | (m) |
| 2014-12-31 | $-404.98M | (m) | (m) | $190.25M | (m) | (m) |
| 2014-09-30 | $-388.86M | (m) | (m) | $166.81M | (m) | (m) |
| 2014-06-30 | $-375.89M | (m) | (m) | $154.99M | (m) | (m) |
| 2014-03-31 | $-352.20M | (m) | (m) | $134.54M | (m) | (m) |
| 2013-12-31 | $-92.94M | (m) | (m) | $112.96M | (m) | (m) |
| 2013-09-30 | $-151.70M | (m) | (m) | $102.53M | (m) | (m) |
| 2013-06-30 | $-137.61M | (m) | (m) | $90.17M | (m) | (m) |
| 2013-03-31 | $-128.37M | (m) | (m) | $87.67M | (m) | (m) |
| 2012-12-31 | $-129.46M | (m) | (m) | $86.57M | (m) | (m) |
| 2012-09-30 | $-54.69M | (m) | (m) | $88.26M | (m) | (m) |
| 2012-06-30 | $-48.98M | (m) | (m) | $90.44M | (m) | (m) |
| 2012-03-31 | $-50.03M | (m) | (m) | $94.02M | (m) | (m) |
| 2011-12-31 | $-54.82M | (m) | (m) | $99.30M | (m) | (m) |
| 2011-09-30 | $-53.64M | (m) | (m) | $102.01M | (m) | (m) |
| 2011-06-30 | $-49.93M | (m) | (m) | $105.20M | (m) | (m) |
| 2011-03-31 | $-48.44M | $96.37M | (m) | $108.03M | (m) | -50.26% |
| 2010-12-31 | $-44.07M | $100.04M | (m) | $106.38M | (m) | -44.05% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-48.11M | $100.53M | (m) | $108.73M | (m) | -47.86% |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | $-27.84M | $96.16M | (m) | $96.88M | (m) | -28.95% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |